THERAPEUTIC MODALITIES Archives - Page 3 of 22

Key Steps in Validating Targeted Protein Degraders

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have...

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Targeted Protein Degraders: Trends, Challenges, and Solutions

Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs). Our platform enables research...

Innovative R&D Strategies for Peptide Drugs in Obesity Treatment

Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across...

Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...

Development of Novel ADC-Resistant Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

AACR 2025 Posters: Sneak Peek

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...

Rational Design and Optimization of a Potent IDO1 PROTAC

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors...

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...

Knowledge Library